SCHEMBL29366389

SCHEMBL29366389

CCc1ccccc1-c1nc(-c2cccc(OC)c2)n[nH]1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 3/20 0.68
NR1H3 Q13133 3/20 0.68
ADORA2A P29274 12/20 0.57
ADORA1 P30542 7/20 0.57
DCUN1D1 Q96GG9 1/20 0.48
TEK Q02763 1/20 0.46
GRK6 P43250 1/20 0.46
DYRK1A Q13627 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
ALPL P05186 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3500575 1.00 NR1H2 (0.68) NR1H2NR1H3ADORA2AADORA1DCUN1D1
SCHEMBL5678433 0.90 NR1H2 (0.64) NR1H2NR1H3ADORA2AADORA1DCUN1D1
SCHEMBL10476810 0.89 NR1H2 (0.67) NR1H2NR1H3ADORA2AADORA1DCUN1D1
SCHEMBL11176066 0.89 NR1H2 (0.67) NR1H2NR1H3ADORA2AADORA1DCUN1D1
SCHEMBL17280037 0.88 NR1H2 (0.50) NR1H2NR1H3ADORA2ANPC1TP53
SCHEMBL10476823 0.86 NR1H2 (0.59) NR1H2NR1H3ADORA2AADORA1DCUN1D1
SCHEMBL11171315 0.84 NR1H2 (0.48) NR1H2NR1H3ADORA2AADORA1NPC1
SCHEMBL10476791 0.84 NR1H2 (0.73) NR1H2NR1H3ADORA2AADORA1DCUN1D1
SCHEMBL11171303 0.83 NR1H2 (0.60) NR1H2NR1H3ADORA2ANPC1TP53
SCHEMBL11172345 0.82 NR1H2 (0.63) NR1H2NR1H3ADORA2AADORA1DCUN1D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022047234-A1 DRUG COMBINATION KITS AND METHODS OF DRUG DELIVERY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-03-03 WO claimed
US-20260144674-A1 Apparatus and Methods for Drug Delivery Using Microneedles CLEARSIDE BIOMEDICAL, INC. (US) 2026-05-28 US disclosed
US-20250345206-A1 APPARATUS AND METHODS FOR OCULAR INJECTION CLEARSIDE BIOMEDICAL, INC. (US) 2025-11-13 US disclosed
US-12350261-B2 Methods and devices for the treatment of ocular diseases in human subjects CLEARSIDE BIOMEDICAL, INC. (US) 2025-07-08 US disclosed
US-20250186253-A1 DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY CLEARSIDE BIOMEDICAL, INC. (US) 2025-06-12 US disclosed
EP-4566672-A2 METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS Clearside Biomedical Inc. (US) 2025-06-11 EP disclosed
EP-3554435-B1 SYSTEMS FOR DELIVERING DRUGS TO RETINAL TISSUE CLEARSIDE BIOMEDICAL INC (US) 2025-06-04 EP disclosed
US-20250152413-A1 SYSTEMS, DEVICES, AND METHODS FOR NEEDLE-LESS OCULAR INJECTIONS CLEARSIDE BIOMEDICAL INC (US) 2025-05-15 US disclosed
EP-3721872-B1 METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS CLEARSIDE BIOMEDICAL INC (US) 2025-01-22 EP disclosed
US-12201558-B2 Apparatus and methods for ocular injection CLEARSIDE BIOMEDICAL, INC. (US) 2025-01-21 US disclosed
US-11596545-B2 Systems and methods for ocular drug delivery CLEARSIDE BIOMEDICAL, INC. (US) 2023-03-07 US disclosed
US-11559428-B2 Apparatus and methods for ocular injection CLEARSIDE BIOMEDICAL, INC. (US) 2023-01-24 US disclosed
EP-2887982-B1 APPARATUS FOR DRUG DELIVERY USING MICRONEEDLES CLEARSIDE BIOMEDICAL INC (US) 2022-11-23 EP disclosed
US-11504431-B2 Formulations for the suprachoroidal space of an eye and methods EMORY UNIVERSITY (US) 2022-11-22 US disclosed
US-20220280341-A1 APPARATUS AND METHODS FOR DRUG DELIVERY USING MICRONEEDLES CLEARSIDE ROYALTY LLC 2022-09-08 US disclosed
US-20220280386-A1 METHODS AND APPARATUS FOR EXTRACTING FLUID FROM CONTAINER CLEARSIDE BIOMEDICAL, INC. 2022-09-08 US disclosed
WO-2022182638-A1 COMPOSITIONS AND METHODS FOR CARDIOMYOCYTE TRANSPLANTATION UNIVERSITY OF WASHINGTON (US) 2022-09-01 WO disclosed
WO-2022076938-A1 APPARATUS AND METHODS OF RETINAL INJECTION CLEARSIDE BIOMEDICAL, INC. (US) 2022-04-14 WO disclosed
WO-2022047234-A1 DRUG COMBINATION KITS AND METHODS OF DRUG DELIVERY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-03-03 WO disclosed
CN-110177527-B Device and method for adjusting insertion depth of needle for medicament delivery 科尼尔赛德生物医学公司 2022-02-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144674-A1 Apparatus and Methods for Drug Delivery Using Microneedles PROKR2, SLC10A2, GLP1R NR1H2 3123/4885NR1H3 3034/4885ADORA2A 2854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.